Introduction
============

Misuse of amphetamine psychostimulants (eg, methylphenidate such as Ritalin^®^, Concerta^®^), amphetamine/dextroamphetamine \[Adderall^®^\], lisdexamfetamine dimesylate \[Vyvanse™\]) and other unsafe self-medication practices among college students are an important and serious threat to student health across the nation's college campuses. Prescriptive stimulants are federally mandated schedule II controlled substances (CIIs), due to their high potential for abuse that may lead to psychological and physical dependence.[@b1-ppa-9-161] According to US Drug Enforcement Administration (DEA) regulations, physicians are authorized to prescribe up to a 90-day supply of a CII substance per visit without refills.[@b2-ppa-9-161] Despite federal prescriptive-stimulant regulations, large-scale college student studies have documented the prevalence of undergraduates using non-prescribed stimulants as 2% to 8%[@b3-ppa-9-161]--[@b5-ppa-9-161] in the past month and 3% to 16% in the past year.[@b5-ppa-9-161]--[@b8-ppa-9-161] In a northeastern university, 34% of respondents reported taking non-prescribed amphetamines.[@b7-ppa-9-161] Another study conducted at a mid-western university indicated that self-reported past-year use of amphetamines significantly increased from 5% in 2003 to 9% in 2013.[@b8-ppa-9-161]

Concurrent use of stimulants with antidepressants is a high-risk behavior and is medically contraindicated[@b9-ppa-9-161] due to potential cytochrome P450 2D6 (CYP2D6) enzyme inhibition and a resulting increase in serotonin levels. Specifically, using stimulants to self-medicate depression is counterproductive, as stimulants can precipitate depressive symptoms and exacerbate existing depression. Likewise, amphetamine stimulants can cause a host of adverse symptoms such as cardiac dysrhythmias, anxiety, high blood pressure, difficulty sleeping, diarrhea, dizziness, and unsteadiness.[@b9-ppa-9-161] Student misperceptions of nonmedical stimulant use as being "physically harmless"[@b10-ppa-9-161]--[@b12-ppa-9-161] are cause for concern. As concurrent use of stimulants, alcohol, and/or other medications is common among college students,[@b8-ppa-9-161],[@b13-ppa-9-161] this suggests that students are mostly unaware of the adverse consequences of such mixed use.[@b10-ppa-9-161],[@b12-ppa-9-161] To further investigating the self-medication practices of undergraduate students, the study reported here focused on concurrent use of amphetamine stimulants and antidepressants, in addition to other drug-use and lifestyle factors.

Methods
=======

Undergraduate students who were 18 years old or older from a large northeastern university were recruited as respondents in an online survey via an email during October of 2011. The university required students to link their university email address to their private email addresses, thus ensuring receipt of listserv emails by all undergraduates. The email briefly described the survey objectives and provided the web link to the survey, which was available for a 2-week period. This message also instructed students to copy and paste the survey web address into a browser to ensure anonymity. The email message was sent to 17,450 students. The response rate was 13.1%; 2,281 surveys were completed.

Survey instrument
-----------------

An ActualMeds™ online survey (designed for touch screen use) that was previously validated by the principal investigator's research team for assessing self-medication behavior in older adults was modified and then adopted for this research study.[@b14-ppa-9-161],[@b15-ppa-9-161] The medication database that is linked to the ActualMeds online survey included such agents as marijuana, methamphetamine, energy drinks (eg, Monster Energy^®^, Red Bull^®^, 5-Hour Energy™, etc), caffeine (ie, pills and gum such as Jolt^®^, Penguin^®^, Blitz^®^, etc), chewing tobacco, ecstasy, protein supplements (eg, whey protein, creatine, Opti-Men™, Muscle Milk^®^, etc), and food (eg, coffee, tea, espresso, soda, milk, carbohydrates, bread, and hot sauce). Colloquial terms for each agent were also used in the survey (eg, molly, weed, juice, coke, and roofies). The research team fact-checked the accuracy of the medication data linked to the online survey and ascertained the survey's usability by testing it four different times before administering the survey.

The survey items included four categories of questions: (1) demographics, (2) lifestyle, (3) health conditions and symptoms, and (4) medication use. Demographic questions inquired about characteristics such as gender, class standing, race/ethnicity, student-group affiliations (eg, sports, groups, sororities, and fraternities), residence (eg, campus or off-campus housing), and most frequented meal locations.

Questions that measure the general lifestyle profile included, for instance, amount of exercise in the last month, hours of sleep per night, smoking status (cigarettes and chewing tobacco), nicotine craving, energy drink/supplement consumption, and the primary medical information source. Respondents were also asked if they had consumed wine, beer, or liquor in the past month. If they selected "yes" to this question, they were prompted to provide a response to questions on the following: (1) the number of drinks they would have on a typical day; (2) how many days a week they drank; (3) what they usually took, if anything, prior to consuming alcohol; (4) what they mixed, if anything, with the alcohol consumed; and (5) what they took, if anything, to treat a hangover. To ensure consistency in drink-size measurement, an image of a standard drink reference was displayed.

Survey questions that assessed respondents' health contained such items as all medical conditions in the past year (via a drop-down menu), the presence of any health symptoms in the past month (via a drop-down menu), and a self-rating of one's own health in the past month (via the scale "poor, fair, average, good, or very good"). Medication-use questions (dichotomously coded) asked respondents which medication they used, if any, to care for common conditions or illnesses such as eye issues, diabetes, low thyroid, depression, pain, anxiety, indigestion, allergies, colds, or sinus problems. Other medication questions queried respondents which medication or supplement they took, if any, to help them sleep, stay awake, improve sexual performance, lose weight, gain muscle, or improve athletic performance. Additional medication questions probed respondents about whether they took any other prescribed or over-the-counter (OTC) medications or nutrition supplements (ie, vitamins, minerals, or herbs).

For the medication-use questions, if respondents answered an affirmative to any of them, they were directed to a database that provided an A--Z drop-down list to identify the agent(s) that they took (including prescribed and OTC medications, nutrition supplements, herbals, and alcohol and tobacco products). Respondents were also given the option to type in the agent(s) they used for each question, if the generic or brand name of the agent was not available in the database. For example, a respondent could report several different pain relievers in response to the question "What did you use for pain in the past month?" For each agent chosen or entered, the respondents were also directed to: (1) answer how many days a week they had taken it over the past month and (2) report how much, when, and how many times they took the agent by clicking on a 24-hour clock face. Following that, respondents were redirected to answer the other remaining questions.

Data analysis
-------------

Of the 2,281 online surveys collected, 280 (12%) incomplete and 25 (1.1%) invalid surveys were removed from the data analysis. Incomplete surveys were those that had three or more missing demographic answers. An example of an invalid survey response contained a positive answer to taking an unrealistic list of the following medications and daily dosages for pain: one Omnaris^®^, seven Zyrtec^®^, twelve marijuana, six ibuprofen, and six Vyvanse. Gender, race/ethnicity, class standing, current residence, group affiliation, self-health reports, number of hours of sleep per night, exercise, health conditions, health symptoms, and medication use were reported as frequencies.

Self-medication frequency associated with the use of each medication was obtained via matching the self-reported medication name/brand with the medication identification numbers extracted from the medication database of the ActualMeds survey. Medication counts were computed based on the number of respondents who answered positively to each single-agent category. To calculate medication-category percentages, each category was divided by the total different number of respondents who provided at least one rationale for the use of an agent. The categorical variables were calculated as frequencies and percentages. Chi-square or Fisher's exact tests, using SAS/STAT^®^ software (v 9.2),[@b16-ppa-9-161] were applied to compare respondents: (1) who reported taking stimulants to those who did not and (2) who reported taking prescription medications for depression concurrently with stimulants to those who did not. The level of significance was set a priori at *P*\<0.05.

Hierarchical binary logistic regressions using the logit function (inverse of the cumulative logistic distribution function) were conducted to evaluate the relationship between sets of predictor variables and stimulant use among respondents who reported taking a prescription medication to treat depression.

Results
=======

The 1,976 complete and reliable surveys (n=1,392; 70% female) represented approximately 11% of the undergraduate population at the university.[@b17-ppa-9-161] Participant class standing was as follows: freshmen (n=539; 27%), sophomores (n=503; 26%), juniors (n=476; 24%), and seniors (n=455; 23%). Overall, 79 (4.0%) survey respondents reported using a stimulant in the past month and 68% of them were female. The university's institutional review board did not permit the investigation of nonmedical or medical use of stimulants among survey respondents; therefore, the use of the word "stimulant" can refer to either prescribed or non-prescribed stimulants in this paper. The stimulants respondents reported using include Adderall, Vyvanse, Ritalin/methylphenidate, Concerta, and dextroamphetamine.

The reported reasons for stimulant use included the following: (1) to improve mental performance (n=61; 77%), (2) to stay awake (n=27; 34%), (3) to mix with alcohol (n=6; 7.6%), (4) to control anxiety/depression (n=5; 6.3%), (5) to prepare for drinking alcohol (n=2; 2.5%), (6) to gain pain relief (n=2; 2.5%), and/or (7) to lose weight (n=1; 1.3%). Six students (7.6%) did not report a reason for use other than "prescribed medication". These results correspond to the rationales of nonmedical use of stimulants found in past studies.[@b18-ppa-9-161]--[@b21-ppa-9-161]

[Table 1](#t1-ppa-9-161){ref-type="table"} presents the comparisons between self-reported stimulant users and non-stimulant users across a set of key variables. Consistent with the current literature that suggests stimulant use is the highest among the Caucasian population,[@b8-ppa-9-161],[@b13-ppa-9-161],[@b22-ppa-9-161]--[@b24-ppa-9-161] race/ethnicity was significant in this study (*P*\<0.05). While 89% of the stimulant users were white, 4% were Asian, and none were black. By comparison, 75% of nonusers were white, 10% were Asian, and 7% were black. The literature suggests that stimulant use is either similar between males and females or higher in the male population.[@b8-ppa-9-161],[@b13-ppa-9-161],[@b20-ppa-9-161]--[@b22-ppa-9-161] No difference was found between genders in relation to stimulant use in this survey. Likewise, an individual's group affiliation, exercise level, health conditions in the past year, sleep, and sources of medication information were not significantly different between stimulant users and nonusers in this study.

Class standing was statistically significant between respondents reporting and not reporting stimulant use (*P*\<0.01). Of respondents indicating stimulant use, 11% were freshmen and 35% were juniors. By contrast, 28% and 24% freshmen and juniors did not report stimulant use, respectively. Current residence was also significantly differentiated (*P*\<0.001). Specifically, 39% of respondents who reported stimulant use lived in an off-campus apartment or fraternity/sorority housing, compared with the 21% of respondents who did not report stimulant use.

Alcohol use was significantly different between stimulant users and nonusers (*P*\<0.001). Among stimulant users, 91% replied "yes" to the question asking whether they drank wine, beer, or liquor, compared with 60% of nonusers who stated the same ([Table 2](#t2-ppa-9-161){ref-type="table"}). These findings confirmed two prior national survey results regarding alcohol and amphetamine-stimulant use among full-time college students.[@b25-ppa-9-161],[@b26-ppa-9-161] Nearly half (46%) of stimulant users who reported drinking alcohol consumed alcohol on 3 or more days per week -- and/or had three or more drinks in one sitting at least once per week -- compared with 36% of non-stimulant users who also reported drinking alcohol. Of respondents reporting stimulant use, 11% indicated using stimulants either to "prepare for drinking" or "to mix with alcohol". Moreover, 52% of stimulant users probably had steady-state levels of amphetamine stimulants in their bloodstream, since they reported using them "daily", "three days or more per week", or "when I remembered to take it". Eighty-nine percent of the students who took stimulants this frequently also reported drinking alcohol, with 53% of them drinking alcohol three or more times per week and/or having three or more drinks in one sitting.

Smoking in the past month was reported by 22% of the students surveyed. This finding is similar to that of the National College Health Assessment -- which documented an overall 24% smoking rate in the prior month -- based on a 2009 survey of 30,093 students from 39 colleges by the American College Health Association.[@b27-ppa-9-161] In the current survey, significantly more (42%) stimulant users reported smoking cigarettes and/or smokeless (chewing) tobacco than nonusers (21%) of stimulants (*P*\<0.001). These findings supported prior results of an American College Health Association--National College Health Assessment survey of 10,220 full-time undergraduates, wherein twice as many stimulant users than nonusers reported smoking cigarettes.[@b26-ppa-9-161] In the current survey, chewing tobacco was reported by 7.6% of stimulant users but only 1.2% of nonusers of stimulants (*P*\<0.001). Furthermore, nicotine craving was a symptom for 32% of stimulant users, compared with only 3.3% of nonusers.

There was no significant difference in energy-drink/caffeine-supplement use between those who used and did not use a stimulant. While energy drinks or caffeine supplements were reported by 2.9% of respondents, only less than 1% of respondents indicated use of caffeine supplements or energy drinks -- before drinking alcohol or mixed with alcohol.

A significant difference was found in the self-rated health report between stimulant users and nonusers (*P*\<0.01). In particular, 24% of stimulant users rated themselves as having fair or poor health in the past month, compared with only 12% of nonusers who stated the same. Health symptoms over the past month identified by respondents who used stimulants were also significantly different from those who did not use stimulants (*P*\<0.001). Specifically, having difficulty concentrating was reported for 58% of stimulant users, compared with 34% of nonusers. The ratios of other health symptoms reported by stimulant users versus nonusers were: (1) fatigue: 66% versus 45%, (2) difficulty sleeping: 66% versus 38%, (3) depression: 33% versus 13%, (4) diarrhea: 39% versus 22%, (5) memory change: 11% versus 3.8%, (6) dizziness: 33% versus 15%, and (7) unsteadiness: 14% versus 6%, respectively. Based on these findings, it appears that stimulant users experienced more negative health symptoms than nonusers.

Pain-reliever (prescription and OTC) use in the past month was reported by 65% of those who used stimulants and 52% of those who did not (*P*\<0.05). The National Survey on Drug Use and Health (NSDUH) survey found 45% of those taking Adderall for nonmedical reasons in the past year also took prescription pain relievers, compared with the 8.7% of those who did not use Adderall.[@b25-ppa-9-161] In the current study 7.6% of stimulant users (who use any amphetamine stimulant including Adderall for any reason) and 2.8% of the nonusers reported taking a prescription pain reliever in the past month (*P*\<0.001).

Concurrent prescriptions for depression ([Table 3](#t3-ppa-9-161){ref-type="table"}) were reported by 19% of those who used stimulants, compared with 4.1% of non-stimulant users (*P*\<0.001). Of those stimulant users indicating depression as a symptom, more than a third (38%) took a selective serotonin reuptake inhibitor (SSRI) or serotonin--norepinephrine reuptake inhibitor (SNRI) to manage their symptoms ([Table 3](#t3-ppa-9-161){ref-type="table"}). Looking at this in a different way, of those students (n=100) who used a prescription for treating depression, 15% had also taken a stimulant in the past month, compared with 3.3% (n=64) of students not reporting the use of prescription depression medication. Of the 15 students reporting taking stimulants and prescription medication for treating depression concurrently, 80% took stimulants three or more times per week and 73% reported taking stimulants daily.

Chi-square analyses found no significant differences, when comparing students who concurrently took medication for depression and stimulants with those who did not take stimulants -- with respect to the following demographic and lifestyle variables -- race/ethnicity, class standing, living/residency, number of hours of sleep per night, exercise, alcohol use, health self-report, health conditions in the past year, or symptoms in the past month. However, students taking both stimulants and prescription medication for depression reported a greater frequency -- for no group affiliation (*P*\<0.05), difficulty sleeping (*P*\<0.05), nicotine craving (*P*\<0.001), and pain-reliever use (*P*\<0.05) -- than students undergoing treatment for depression without reporting stimulant use.

Hierarchical binary logistic regressions using the logit function (inverse of the cumulative logistic distribution function) evaluated the relationship between sets of predictor variables and stimulant use among respondents who reported taking a prescription medication to treat depression. The predictor variables, chosen based on the results of two-tailed Fisher's exact tests ([Tables 1](#t1-ppa-9-161){ref-type="table"} and [3](#t3-ppa-9-161){ref-type="table"}), were: no group affiliation, difficulty sleeping, nicotine craving, and prescription/OTC pain-reliever use. Bivariate correlations (zero-order Pearson's correlations) among the independent variables and dependent variable (user status) were computed to identify interactions. The Pearson correlation of nicotine craving with difficulty sleeping was 0.222 (*P*=0.026). Therefore, this interaction of nicotine craving × difficulty sleeping was also assessed in the regressions.

Results from the initial binary logistic regression (additive model) are shown in [Table 4](#t4-ppa-9-161){ref-type="table"} (goodness-of-fit tests for this model are shown in [Table 5](#t5-ppa-9-161){ref-type="table"}). Predictor values with *P*-values less than 0.1 were retained (ie, prescription/OTC pain-reliever use was omitted) in subsequent regressions. Backward stepwise binary logistic regression was conducted using the remaining significant predictor variables: no group affiliation, difficulty sleeping, and nicotine craving. Since bivariate correlations found a significant correlation of difficulty sleeping with nicotine craving, the interaction variable "difficulty sleeping × nicotine craving" was also assessed. Two additional binary logistic regressions were performed by entering the main effects before interaction effects (ie, no group affiliation entered before difficulty sleeping × nicotine craving, followed by \[1\] nicotine craving \[lowest *P*-value in the additive model\] and \[2\] either difficulty sleeping or no group affiliation).

Difficulty sleeping did not improve the model *P*-value, adjusted R-squared, or goodness-of-fit statistics. Therefore, the final models tested no group affiliation, difficulty sleeping × nicotine craving, and nicotine craving. Removing the interaction term and retaining nicotine craving and no group affiliation resulted in lower chi-squares and *P*-values, indicating improved goodness-of-fit tests and a good model fit ([Tables 6](#t6-ppa-9-161){ref-type="table"} and [7](#t7-ppa-9-161){ref-type="table"}).

Discussion
==========

The negative health consequences on the central nervous system associated with concurrent use of amphetamines with alcohol and other drugs have been well documented in the medical literature. As aforementioned, college students often mix prescription drugs -- such as amphetamine stimulants and antidepressants with alcohol, other drugs, OTC medicines, and energy drinks -- without being aware of the potentially dangerous interaction effects between these substances.[@b8-ppa-9-161],[@b28-ppa-9-161],[@b29-ppa-9-161] Specifically, alcohol increases the release of methylphenidate from extended-release formulations of stimulants, which further increases the risk of anxiety, tachycardia, and high blood pressure.[@b9-ppa-9-161] Concurrent use of stimulants (either amphetamines or caffeine) and alcohol can increase wakefulness and mask the depressant effects of alcohol on the central nervous system, until much larger amounts of alcohol have been consumed.[@b30-ppa-9-161]

Furthermore, stimulants can precipitate depressive symptoms. Thus, self-medicating depression with stimulants is counterproductive, as stimulants can exacerbate existing depression.[@b9-ppa-9-161] Although methylphenidate and SSRIs have been prescribed to treat adolescents with attention deficit hyperactivity disorder (ADHD) and comorbid depression exhibiting symptoms of apathy and hypersomnia,[@b31-ppa-9-161],[@b32-ppa-9-161] concurrent use of stimulants with antidepressants without close medical monitoring could result in rare but serious adverse reactions for the following reasons. First, amphetamines are metabolized by the CYP2D6 enzyme in the liver. Genetic polymorphisms of CYP2D6 are common; poor metabolizers of CYP2D6 have higher blood levels of substrates metabolized by the enzyme.[@b33-ppa-9-161] Commonly prescribed antidepressants such as SSRIs can inhibit CYP2D6, which can in turn increase serum concentrations and side effects of amphetamines.[@b9-ppa-9-161],[@b34-ppa-9-161] Second, amphetamines can increase serotonin release and inhibit reuptake; concurrent use of amphetamines with SSRIs can lead to dangerously high extracellular serotonin levels (serotonin syndrome).[@b9-ppa-9-161],[@b34-ppa-9-161] Other medications used to treat depression can also lead to serotonin syndrome when used with amphetamines. These include SNRIs, St John's wort, bupropion (Wellbutrin), and lithium.[@b34-ppa-9-161]

Early symptoms of serotonin syndrome include tachycardia, shivering, diarrhea, diaphoresis, muscle cramps, agitation, and elevated body temperature. These are followed by hypertension, hyperthermia, hyperreflexia, delirium, tremors, and rigidity. If not treated, hypertensive crisis and severe hyperthermia can result in death.[@b9-ppa-9-161],[@b34-ppa-9-161] Stimulants also increase blood pressure by increasing extracellular norepinephrine and dopamine. Moreover, concurrent use of stimulants with either SNRIs or bupropion (with a similar structure to amphetamine) can increase blood pressure.[@b9-ppa-9-161]

The actual incidence of serotonin syndrome from concurrent use of medications used to treat depression and stimulants is unknown. Cooper and Sejnowski[@b34-ppa-9-161] have reviewed the agents involved and the increasing frequency of serotonin syndrome over time, as SSRIs and SNRIs have become more frequently prescribed. The 2012 "Annual report of the American Association of Poison Control Centers' National Poison Data System" identified 47,115 toxic SSRI/SNRI exposures (the majority of which involved concurrent ingestion of other agents) and 89 deaths.[@b35-ppa-9-161] Boyer[@b36-ppa-9-161] states that serotonin syndrome may be underrepresented in the surveillance data because: (1) the symptoms of serotonin syndrome may be attributed to another cause, (2) mild symptoms may resolve within 24 to 74 hours or are ignored or dismissed, or (3) the clinician does not suspect or is not aware of the condition (a study in 1999 found that 85% of physicians were unaware of serotonin syndrome as a clinical diagnosis[@b37-ppa-9-161]). Future studies should aim to assess the prevalence of both CYP2D6 inhibition and the risk of serotonin syndrome related to stimulants and concurrently prescribed medications for treatment of depression.

Currently, prescribing information for SSRIs and SNRIs states that they inhibit hepatic CYP2D6; however, the examples of medications metabolized by CYP2D6 that should not be taken with SSRIs/SNRIs exclude amphetamines. Also, prescribing information for SSRIs and SNRIs do not mention amphetamines among the drugs[@b34-ppa-9-161] that can precipitate serotonin syndrome, when taken concurrently with SSRIs or SNRIs. Recent continuing education programs for prescribers and pharmacists[@b34-ppa-9-161],[@b38-ppa-9-161],[@b39-ppa-9-161] will help clinicians become more aware of the etiology, epidemiology, diagnosis, and treatment of serotonin syndrome. However, the US Food and Drug Administration should consider requiring statements on both prescribing information and package inserts -- regarding the potential increased risk of adverse effects from concurrent use of amphetamines and prescription antidepressants -- if sufficient research evidence supports such a policy.

A recent investigation of medical versus nonmedical use of prescription drugs among college students[@b8-ppa-9-161] reported the following outcomes, respectively: (1) sleep aids: 3.3% versus 2%, (2) sedative/anxiety medication: 3.4% versus 2.9%, (3) stimulants: 2.2% versus 5.4%, and (4) prescription pain relievers: 24.4% versus 9.3%. Past studies have also found that undergraduate students in the United States engaged in nonmedical use of stimulants much more frequently than their non-college-attending counterparts.[@b28-ppa-9-161],[@b40-ppa-9-161]

Based on the findings discussed, it is clear that the college lifestyle chosen by some students -- characterized by sleep deprivation, mixing alcohol and drug use at social events, using stimulants as "study aids", and the like -- is a serious environmental and public health risk across the country. In a recent college study, approximately 50% of respondents who reported frequent or non-oral use of nonmedical prescription stimulants in the past month also reported depressed mood.[@b41-ppa-9-161]

The present study contributes to the literature by examining the prevalence of concurrent use of amphetamine stimulants and prescribed medication to treat depression among college students. Unlike other previous research, this study also investigated self-health rating, symptomatology, and concurrently self-medication practices (including how often and when agents were ingested) among those who used a stimulant concurrent with prescribed medication to treat depression.

Of the 1,976 valid survey responses, 4.0% of survey respondents reported using stimulants in the past month. This stimulant use percentage falls within the 2%--8% range of previously published surveys.[@b3-ppa-9-161],[@b4-ppa-9-161],[@b8-ppa-9-161],[@b41-ppa-9-161] The current survey was conducted several weeks before the midterm exams rather than during the midterm or final exam period when stimulant use typically increases.[@b10-ppa-9-161],[@b42-ppa-9-161] This scenario may also explain the wide range in reported prevalence rates among college students in previous studies.[@b26-ppa-9-161] Although respondents were informed of the anonymous nature of the survey (and that illicit drug use was not an objective of the survey), stimulant use could have been under reported due to their fear associated with the consequences of reporting illicit drug use.

Compared with non-stimulant users, self-health was rated more poorly and negative health symptoms were reported as more significant among stimulant users. Undesirable health symptoms reported included depression, diarrhea, difficulty sleeping, fatigue, dizziness and unsteadiness, difficulty concentrating, and nicotine craving. Of respondents mentioning amphetamine-stimulant use, 33% indicated symptoms from depression, which is more than twice greater than the 13% of respondents who reported no stimulant use. Tobacco use was also doubly as common and nicotine craving was nine times more prevalent -- among stimulant users than among nonusers -- whether or not they were taking a prescription medication to treat depression. The findings regarding nicotine craving are of particular interest as recent studies found depressive symptomatology in amphetamine users to be significantly associated with nicotine craving and smoking-cessation difficulty.[@b43-ppa-9-161],[@b44-ppa-9-161]

Even though the percentage of respondents in the current study who took both stimulants and prescription medication for depression (0.8%) is not high, the co-mingling of these two types of substances could cause CYP2D6 enzyme inhibition and potentially increased serum levels of amphetamine and serotonin with severe health consequences for these students. An important component of adherence to an antidepressant regimen is avoiding concurrent use of other medications that can cause adverse drug--drug interactions. Students taking prescription medication for depression were found to be four times more likely to use amphetamine stimulants than those not taking prescribed medication for depression. Of stimulant users with symptoms of depression, more than a third reported taking a prescription medication for treating depression. The survey respondents being treated for depression reported obtaining medication information from their primary care providers (including 47% of those who also used stimulants and 37% of those who did not use stimulants). In contrast, of the stimulant users who did not take prescription medication for treating depression, none reported consulting their primary care provider for such information.

Of the students who reported using stimulants and prescription agents to treat depression, 93% also reported anxiety as a condition in the past year. It appears unlikely that these stimulants were both prescribed and monitored by the prescriber(s). If the stimulants were indeed legally prescribed to treat ADHD and comorbid depression in students exhibiting symptoms of apathy and hypersomnia,[@b31-ppa-9-161],[@b32-ppa-9-161] then anxiety (a possible side effect of stimulant use) may have resulted without prescriber monitoring. It should be noted that in this sample (biased with predominantly white females), the "predictor" variables in the binary logistic regression model are not actual predictors of whether a student taking prescribed medication for depression will use stimulants. They are variables associated with the respondent reporting stimulant use. Future longitudinal studies should collect data on symptoms along with patterns of drug and alcohol use to determine if these (or other) variables predispose students taking a prescription for depression therapy to use stimulants or vice versa. Based on the results of this study, it is considered prudent for clinicians monitoring students under treatment for depression to continuously inquire about their concurrent medication use (prescribed, OTC, and illicit agents), sleep patterns, participation in extracurricular groups, and symptoms of nicotine craving.

Given the potential risks and side effects of stimulant use alone or concurrently with alcohol and other medications such as antidepressants, health care providers should query students about their symptoms and self-medication practices, in addition to providing tailored education at the point of care during each visit.[@b15-ppa-9-161] Students with symptoms of depression and/or taking antidepressants should be given explicit warnings concerning amphetamine-stimulant use. They should be counseled at all points of care about the symptoms of serotonin syndrome and potential interactions with agents with which they may self-medicate such as amphetamines as well dextromethorphan cough suppressants, St John's wort, ginseng, cocaine, ecstasy (3,4-methylenedioxy methamphetamine \[MDMA\]), and/or mescaline.

Limitations
===========

The online survey adopted by the study had several limitations, even though it was efficient in reaching a large participant pool. First, respondents could not ask for clarification of the survey content, which may have resulted in incorrect answers, incomplete surveys, or aborted submissions. Second, the length of time required for completing the survey could vary among respondents. For instance, when the respondents answered "yes" to a self-medication question in the survey, they were prompted with an additional question and so on. Hence, respondents could answer "no" to selected questions -- or skip entering medication-use information in the text-space provided -- to avoid further prompts. Third, the university considers students a "vulnerable population", therefore the institutional review board did not permit the investigation of: (1) whether stimulants were used for medical or nonmedical purposes, (2) how medications were acquired, or (3) whether individual students were diagnosed with ADHD (which is usually treated with stimulants). Fourth, the small number of males in the sample might have reduced the range of male responses and resulted in a bias.

That only 2.9% of respondents reported using an energy drink in the past month was unexpected. This stands in contrast to the results of Woolsey et al's 2009 online survey[@b29-ppa-9-161] that found 83% of the 267 respondents reported using energy drinks in the past year and 15% indicated using energy drinks only when drinking alcohol. There may be two reasons why the results from Woolsey et al's[@b29-ppa-9-161] study are different from those of the current study. First, energy drink users may have been over represented in the Woolsey et al[@b29-ppa-9-161] study, which focused on surveying energy drink use and had a very low response rate. Second, the low reporting rate of energy drink use in the current study might have in part resulted from the recent state ban on energy drinks (and associated public relations campaign), which could have led to a temporary drop in such use during the survey period.

Conclusion
==========

As far as the authors are aware, this study is the first to have assessed self-health rating, symptomatology, and polypharmacy among college students' concurrent use of amphetamine stimulants and medications prescribed for treatment of depression. Further investigation of knowledge and self-medication practices of college students is needed to increase our understanding of how best to educate and counsel students.

Based on the results of this study, colleges and universities should develop, implement, and evaluate preventative and intervention programs -- aimed at reducing student misconceptions about the dangers of stimulant use -- and the risks of concurrent use of stimulants with alcohol, tobacco, antidepressants, and/or other drugs. This education content could be easily added to any existing substance-abuse prevention programs. These programs should also be aimed at establishing a correct social norm regarding prescription stimulant use; this correct norm would dictate that prescription stimulants are and should be intended for medical use only.

Continuing education programs for health providers of college students (both in the community and at student health services) could target improving provider knowledge of potential adverse interactions of stimulants with alcohol, tobacco, and other drugs (antidepressants in particular). Additional training for providers and preprofessional students should improve their skills in assessing student self-medication practices -- as well as identifying and counseling students with symptoms of depression -- associated with the use of stimulants. These efforts will promote and increase safe self-medication literacy and practices among college students to improve their medication adherence, physical health, and psychological well-being.
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###### 

Demographic characteristics of stimulant users and nonusers

  Characteristic            Users, n (%)   Nonusers, n (%)   *χ*^2^ (*P*-value)   Use Rx for depression   *χ*^2^ (*P*-value)   
  ------------------------- -------------- ----------------- -------------------- ----------------------- -------------------- ------------------------------------------------
  Gender                                                     NS                                                                NS
   Female                   54 (68)        1,338 (71)                             12 (80)                 78 (92)              
   Male                     25 (32)        559 (29)                               3 (20)                  7 (8.2)              
  Race/Ethnicity                                             12.5 (0.029)                                                      
   White                    70 (89)        1,421 (75)                             12 (80)                 77 (91)              NS[a](#tfn1-ppa-9-161){ref-type="table-fn"}
   Asian                    3 (3.8)        185 (9.8)                              1 (1.6)                 2 (2.4)              
   Black/African American   0 (0)          132 (7)                                0 (0)                   0 (0)                
   Hispanic                 2 (2.5)        74 (3.9)                               1 (6.7)                 3 (3.5)              
   More than one race       1 (1.2)        49 (2.6)                               0 (0)                   2 (2.4)              
   Other                    3 (3.8)        36 (1.9)                               0 (0)                   0 (0)                
  Class standing                                             11.22 (0.011)                                                     NS[a](#tfn1-ppa-9-161){ref-type="table-fn"}
   Freshman                 11 (14)        528 (28)                               4 (2.7)                 15 (18)              
   Sophomore                17 (22)        486 (26)                               2 (13)                  22 (26)              
   Junior                   28 (35)        448 (24)                               3 (20)                  24 (28)              
   Senior                   22 (28)        433 (23)                               6 (40)                  24 (28)              
  Living/residency                                           39.78 (\<0.001)                                                   NS[a](#tfn1-ppa-9-161){ref-type="table-fn"}
   Dorm room                39 (49)        1,366 (72)                             8 (53)                  56 (66)              
   Off-campus apartment     27 (34)        371 (20)                               5 (33)                  23 (27)              
   At home                  3 (3.8)        114 (6)                                2 (13)                  5 (5.9)              
   Sorority/fraternity      4 (5)          14 (0.7)                               0 (0)                   0 (0)                
   Other                    5 (6.3)        30 (1.6)                               0 (0)                   1 (1.2)              
   No answer                1 (1.2)        2 (0.1)                                0 (0)                   0 (0)                
  Group affiliation                                          NS                                                                NS[a](#tfn1-ppa-9-161){ref-type="table-fn"}
   None                     24 (30)        514 (27)                               8 (53)                  20 (24)              0.028[b](#tfn2-ppa-9-161){ref-type="table-fn"}
   Sorority/fraternity      16 (20)        252 (13)                               1 (6.7)                 13 (15)              
   Club sports team         8 (10)         200 (10)                               1 (6.7)                 2 (2.4)              
   Intramural sports team   17 (22)        424 (22)                               1 (6.7)                 16 (19)              
   Preprofessional group    21 (27)        499 (26)                               2 (13)                  23 (27)              
   Cultural-center group    6 (7.6)        256 (13)                               2 (13)                  7 (8.2)              
   Division 1 sports team   3 (3.8)        60 (3.2)                               1 (6.7)                 6 (7.1)              
   Music -- dance group     4 (5)          187 (9.9)                              1 (6.7)                 5 (5.9)              
   Student government       0 (0)          119 (6.3)                              0 (0)                   9 (11)               

**Notes:**

Chi-square unreliable as more than 20% of cells had frequencies \<5

Fisher's exact test.

**Abbreviations:** NS, nonsignificant; Rx, prescription(s).

###### 

Lifestyle characteristics of stimulant users and nonusers

  Characteristic                   Users, n (%)   Nonusers, n (%)                                      *χ*^2^ (*P*-value)                                 Use Rx for depression   *χ*^2^ (*P*-value)   
  -------------------------------- -------------- ---------------------------------------------------- -------------------------------------------------- ----------------------- -------------------- ---------------------------------------------
  Sleep per night, hours                                                                               NS                                                                                              NS[b](#tfn5-ppa-9-161){ref-type="table-fn"}
   Under 5                         3 (3.8)        66 (3.5)                                                                                                2 (13)                  1 (1.2)              
   5--6                            33 (42)        748 (39)                                                                                                6 (40)                  34 (40)              
   7--8                            39 (49)        990 (52)                                                                                                4 (27)                  39 (46)              
   Over 8                          4 (5.1)        92 (4.8)                                                                                                3 (20)                  11 (13)              
  Exercise                                                                                             NS                                                                                              NS[b](#tfn5-ppa-9-161){ref-type="table-fn"}
   A few times a month             20 (25)        466 (25)                                                                                                5 (33)                  28 (33)              
   A few times a week              35 (44)        721 (38)                                                                                                4 (27)                  23 (27)              
   Daily                           7 (8.9)        268 (14)                                                                                                0 (0)                   16 (19)              
   Once a week                     4 (5.1)        231 (12)                                                                                                1 (6.7)                 7 (8.2)              
   Not at all                      13 (16)        211 (11)                                                                                                5 (33)                  11 (13)              
  Alcohol use                                                                                          23.43 (\<0.001)                                                                                 NS[b](#tfn5-ppa-9-161){ref-type="table-fn"}
   Yes                             72 (91)        1,143 (60)                                                                                              11 (73)                 59 (69)              
   No                              2 (2.5)        273 (14)                                                                                                0 (0)                   10 (12)              
   I never drink                   5 (6.3)        346 (18)                                                                                                4 (27)                  14 (16)              
   No answer                       0 (0)          135 (7.1)[a](#tfn4-ppa-9-161){ref-type="table-fn"}                                                      0 (0)                   2 (2.4)              
  Tobacco use                                                                                                                                                                                          
   Cigarettes or chewing tobacco   33 (42)        392 (21)                                             \<0.001[c](#tfn6-ppa-9-161){ref-type="table-fn"}   0 (0)                   13 (15)              NS[c](#tfn6-ppa-9-161){ref-type="table-fn"}
   Chewing tobacco                 6 (7.6)        23 (1.2)                                             \<0.001[c](#tfn6-ppa-9-161){ref-type="table-fn"}   0 (0)                   0 (0)                NS[c](#tfn6-ppa-9-161){ref-type="table-fn"}
   None                            46 (58)        1,505 (79)                                                                                              15 (100)                72 (85)              
  Energy drinks/supplements        4 (5.1)        54 (2.8)                                             NS[c](#tfn6-ppa-9-161){ref-type="table-fn"}        0 (0)                   1 (1.2)              NS[c](#tfn6-ppa-9-161){ref-type="table-fn"}
  Sources of medical information                                                                       NS                                                                                              NS[b](#tfn5-ppa-9-161){ref-type="table-fn"}
   Family                          45 (57)        1,221 (63)                                                                                              3 (20)                  44 (52)              
   Labels                          20 (25)        438 (23)                                                                                                6 (40)                  22 (26)              
   Friends                         12 (15)        277 (15)                                                                                                3 (20)                  3 (3.5)              
   Primary care provider           7 (8.9)        262 (14)                                                                                                7 (47)                  31 (37)              
   Magazines                       4 (5.1)        40 (2.1)                                                                                                0 (0)                   1 (1.2)              
   Coach                           0 (0)          17 (0.9)                                                                                                0 (0)                   0 (0)                

**Notes:**

Class standings were: 20% freshman, 17% sophomore, 37% junior, 27% senior.

Chi-square unreliable as more than 20% of cells had frequencies \<5.

Fisher's exact test.

**Abbreviations:** NS, nonsignificant; Rx, prescription(s).

###### 

Health conditions and symptoms of stimulant users and nonusers

  Characteristic                                                                 Users, n (%)                                        Nonusers, n (%)   *χ*^2^ (*P*-value)                                 Use Rx for depression                                *χ*^2^ (*P*-value)   
  ------------------------------------------------------------------------------ --------------------------------------------------- ----------------- -------------------------------------------------- ---------------------------------------------------- -------------------- --------------------------------------------------
  Health self-report                                                                                                                                   12.79 (0.005)                                                                                                                NS[a](#tfn8-ppa-9-161){ref-type="table-fn"}
   Good/very good                                                                38 (48)                                             1,213 (64)                                                           5 (33)                                               35 (41)              
   Average                                                                       22 (28)                                             459 (24)                                                             5 (33)                                               33 (39)              
   Fair                                                                          15 (19)                                             174 (9.2)                                                            3 (20)                                               10 (12)              
   Poor                                                                          4 (5.1)                                             49 (2.6)                                                             2 (13)                                               7 (8.2)              
   No answer                                                                     0 (0)                                               2 (0.1)                                                              0 (0)                                                0 (0)                
  Health conditions in the last year[c](#tfn10-ppa-9-161){ref-type="table-fn"}                                                                         NS                                                                                                                           NS[a](#tfn8-ppa-9-161){ref-type="table-fn"}
   Anxiety                                                                       40 (51)                                             436 (23)                                                             14 (93)                                              69 (81)              
   Depression[d](#tfn11-ppa-9-161){ref-type="table-fn"}                          24 (32)                                             239 (13)                                                             13 (87)                                              63 (74)              
   Asthma                                                                        10 (13)                                             236 (12)                                                             0 (0)                                                9 (11)               
   Irregular heartbeat                                                           4 (5.1)                                             68 (3.6)                                                             2 (13)                                               3 (3.5)              
   High blood pressure                                                           2 (2.5)                                             42 (2.2)                                                             0 (0)                                                0 (0)                
   High cholesterol                                                              1 (1.3)                                             51 (2.7)                                                             0 (0)                                                0 (0)                
  Health symptoms in the past month                                                                                                                    300.3 (\<0.001)                                                                                                              NS[a](#tfn8-ppa-9-161){ref-type="table-fn"}
   Headache                                                                      58 (73)                                             1,216 (64)                                                           14 (93)                                              64 (75)              
   Difficulty sleeping                                                           52 (66)                                             717 (38)                                                             13 (87)                                              44 (52)              0.012[b](#tfn9-ppa-9-161){ref-type="table-fn"}
   Fatigue                                                                       52 (66)                                             856 (45)                                                             11 (73)                                              55 (65)              
   Difficulty concentrating                                                      46 (58)                                             647 (34)                                                             11 (73)                                              45 (53)              
   Cough                                                                         41 (52)                                             793 (42)                                                             6 (40)                                               32 (38)              
   Cold                                                                          38 (48)                                             1,078 (57)                                                           6 (40)                                               42 (49)              
   Pain                                                                          36 (46)                                             703 (37)                                                             9 (60)                                               37 (44)              
   Diarrhea                                                                      31 (39)                                             422 (22)                                                             9 (60)                                               20 (24)              
   Depression                                                                    26 (33)[d](#tfn11-ppa-9-161){ref-type="table-fn"}   253 (13)                                                             9 (60)                                               50 (59)              
   Dizziness                                                                     26 (33)                                             290 (15)                                                             6 (40)                                               18 (21)              
   Nicotine craving                                                              25 (32)                                             62 (3.3)                                                             6 (40)                                               4 (4.7)              \<0.001[b](#tfn9-ppa-9-161){ref-type="table-fn"}
   Weight gain                                                                   17 (22)                                             306 (16)                                                             4 (27)                                               18 (21)              
   Weight loss                                                                   11 (14)                                             210 (11)                                                             2 (13)                                               12 (14)              
   Unsteadiness                                                                  11 (14)                                             107 (5.6)                                                            2 (13)                                               5 (5.9)              
   Constipation                                                                  10 (13)                                             222 (12)                                                             3 (20)                                               15 (18)              
   Skin change                                                                   10 (13)                                             130 (6.8)                                                            2 (13)                                               7 (8.2)              
   Memory change                                                                 9 (11)                                              72 (3.8)                                                             2 (13)                                               5 (5.9)              
   Vision changes                                                                7 (8.9)                                             90 (4.7)                                                             1 (6.7)                                              6 (7.1)              
   Bladder problems                                                              7 (8.9)                                             103 (5.4)                                                            2 (13)                                               6 (7.1)              
   Falls or near fall                                                            4 (5.1)                                             73 (3.8)                                                             2 (14)                                               4 (4.7)              
   Taste/smell change                                                            3 (3.8)                                             30 (1.6)                                                             0 (0)                                                0 (0)                
  Prescription/OTC pain-reliever use                                             51 (65)                                             983 (52)          0.026[b](#tfn9-ppa-9-161){ref-type="table-fn"}     12 (80)                                              41 (48)              0.027[b](#tfn9-ppa-9-161){ref-type="table-fn"}
  Prescription pain-reliever use                                                 6 (7.6)                                             54 (2.8)          \<0.001[b](#tfn9-ppa-9-161){ref-type="table-fn"}   1 (6.7)                                              5 (5.9)              NS[b](#tfn9-ppa-9-161){ref-type="table-fn"}
  Prescription for depression                                                    15 (19)[e](#tfn12-ppa-9-161){ref-type="table-fn"}   77 (4.1)          \<0.001[b](#tfn9-ppa-9-161){ref-type="table-fn"}   15 (100)[e](#tfn12-ppa-9-161){ref-type="table-fn"}   85 (100)             

**Notes:**

Chi-square unreliable as more than 20% of cells had frequencies \<5

Fisher's exact test

Other conditions with frequencies \<2% were: arthritis, blood clots in the legs, cancer, diabetes, kidney disease, low thyroid, ulcer

Concurrent medications used for depression were reported by eleven (48%) users reporting symptoms of depression; of these, two were nonprescription

Medications prescribed for depression reported were: SSRIs (9), SSRI/SNRI (1), Wellbutrin (bupropion; 2), lithium (1), Mirapex^®^ (pramipexole; 1), Trileptal^®^ (oxcarbazepine; 1).

**Abbreviations:** NS, nonsignificant; OTC, over the counter; Rx, prescription(s); SNRI, serotonin--norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

###### 

Binary logistic regression model (additive) predicting stimulant use among those taking prescription medication for depression

  Predictor                  Coefficient   SE coefficient   *Z*     *P*-value   Odds ratio   95% CI   
  -------------------------- ------------- ---------------- ------- ----------- ------------ -------- -------
  Constant                   −4.37379      1.03028          −4.25   0.000                             
  No group affiliation       1.36867       0.704357         1.94    0.052       3.93         0.99     15.63
  Difficulty sleeping        1.69038       0.880265         1.92    0.055       5.42         0.97     30.44
  Nicotine craving           2.14449       0.798576         2.69    0.007       8.54         1.78     40.84
  Rx/OTC pain-reliever use   0.806254      0.762883         1.06    0.291       2.24         0.50     9.99

**Notes:** Log-likelihood −30.705. Test that all slopes are zero: G=22.804, *df*=4, *P*-value=0.000.

**Abbreviations:** CI, confidence interval; *df*, degrees of freedom; OTC, over the counter; Rx, prescription; SE, standard error.

###### 

Goodness-of-fit tests

  Method             Chi-square   *df*   *P*-value
  ------------------ ------------ ------ -----------
  Pearson            8.94813      7      0.256
  Deviance           9.82565      7      0.199
  Hosmer--Lemeshow   3.74996      4      0.441

**Abbreviation:** *df*, degrees of freedom.

###### 

Binary logistic regression statistics for predictors of user status among respondents taking prescription medication for depression, final model

  Predictor              Coefficient   SE coefficient   *Z*     *P*-value   Odds ratio   95% CI   
  ---------------------- ------------- ---------------- ------- ----------- ------------ -------- -------
  Constant               −2.69485      0.483689         −5.57   0.000                             
  No group affiliation   1.33104       0.644333         2.07    0.039       3.78         1.07     13.38
  Nicotine craving       2.61942       0.775016         3.38    0.001       13.73        3.01     62.70

**Notes:** Log-likelihood --33.733. Test that all slopes are zero: G=16.749, *df*=2, *P*-value=0.000.

**Abbreviations:** CI, confidence interval; *df*, degrees of freedom; SE, standard error.

###### 

Goodness-of-fit tests

  Method                   Chi-square   *df*   *P*-value
  ------------------------ ------------ ------ -----------
  Pearson                  0.0336663    1      0.854
  Deviance                 0.0331446    1      0.856
  Hosmer--Lemeshow         0.0066045    1      0.935
  Brown:                                       
   General alternative     0.0336629    2      0.983
   Symmetric alternative   0.0321470    1      0.858

**Abbreviation:** *df*, degrees of freedom.
